T1052

Proglumide (Binoside) is a cholecystokinin antagonist, which blocks both the CCKA and CCKB subtypes. Proglumide is a drug that exerts an inhibitory effect on gastric secretion and reduces gastrointestinal motility. It is used clinically in the drug therapy of gastrointestinal ulcers.

β-NF-JQ1 is a PROTAC that recruits aryl hydrocarbon receptor E3 (AhR E3) ligase to target proteins. Using β-NF as an AhR ligand, it targets bromodomain (BRD)-containing proteins and induces AhR and BRD protein interactions. β-NF-JQ1 exhibits potent anticancer activity associated with protein knockdown activity.

BET-IN-2 is a BET inhibitor with an IC50 of 52 nM for BRD4-BD1.

ODM-207 (BET-IN-4) is a potent inhibitor of BRD4.

BET-IN-6, a ligand with potent and high affinity for inhibiting BRD2/BRD4, plays a crucial role in the synthesis of PROTAC BRD2/BRD4 degrader-1 [1], targeting the protein BRD2/4.

β3-AR agonist 1 is a highly selective, and orally available agonist of β3-adrenergic receptor (EC50: 18 nM), being inactive to β1-, β2-, and α1A-AR (β1/β3, β2/β3, and α1A/β3>556-fold).

β-Cryptoxanthin is isolated from Satsuma mandarin orange with an anti-stress effect. It is an oxygenated carotenoid and an antioxidant.

SCD1 inhibitor-4 is stearoylCoA desaturase-1 (SCD1) inhibitor. SCD1 inhibitor-4 can be used for the research of diabetes.

Betrixaban-D6 is a deuterium-labeled Betrixaban. Betrixaban (T4341) is a selective and orally efficacious FXa inhibitor.

Bexarotene-D4 is a deuterium-labeled Bexarotene (T6410) (LGD1069). Bexarotene (T6410) is a selective RXR agonist used in the treatment of cutaneous T-cell lymphoma.

BF-168 is a candidate probe for PET and specifically recognizes both neuritic and diffuse plaques (Ki: 6.4 nM for Aβ1-42).